🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Featured: The Landmark Series: Neoadjuvant Therapy for Locally Advanced #RectalCancer Zachary Bunjo Tarik Sammour ow.ly/ToSM50WhuPK @jeffreyfarma Syed A. Ahmad

1/3 🫁 #TTF-1 is a new marker to identify patients best suited for #lung cancer KRAS inhibitors 🫁 🫁 #Sotorasib - #KRAS G12C mut 🫁 🌟 #Lung cancer patients with high #TTF-1 expression had improved survival outcomes after treatment with the #KRAS inhibitor #Sotrasib.

📢 New in Cancer Cell: Radiotherapy is essential for local control—but can it unintentionally accelerate growth of distant metastases? We examine how RT-induced EGFR signaling and immune modulation may fuel metastatic progression. 🧠🧬🔬 Read: doi.org/10.1016/j.ccel…

❄️Winter of cancer immunotherapy is here. 𝐀𝐥𝐥-𝐜𝐨𝐦𝐞𝐫𝐬 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 & 𝐍𝐞𝐭𝐰𝐨𝐫𝐤-𝐞𝐟𝐟𝐞𝐜𝐭 slowed progress-we’ve hit a plateau. Time to prioritize innovation over convention! Editorial out in JTO & JTO CRR bit.ly/4eEVcv4 Fabio Salomone Antonio Nuccio

I try, often unsuccessfully, to not post while on vacation but this is just too important. Hot of the Arvind Dasari, MD, MS et al. press. New SEER data. Increasing incidence and prevalence, owing to earlier and likely largely incidental diagnoses. Improving OS too🙂 jamanetwork.com/journals/jaman…

🔥 Primary tumor resection in Stage IV BC? Overall, no OS benefit in JCOG1017 trial, but very interesting results. 👉 Huge benefit in local control 👉Metastatic BC is heterogeneous (e.g. oligometastatic, subtypes, treatments response) Not for all, but an option for some?

Total neoadjuvant therapy (TNT) in rectal cancer: A comprehensive review; JAMA Oncology 2025 This review summarizes TNT in LARC (T3–T4 and/or N+). TNT increased pCR up to 28%, lower DM (24% vs 30%) & 43% organ preservation with cCR. jamanetwork.com/journals/jamao… OncoAlert

ESOPEC trial: Recurrence patterns. 🔗 ascopubs.org/doi/10.1200/JC… 📊 CROSS vs FLOT in resectable esophageal ADC: ✔️ Systemic relapse: 67% vs 46% ✔️ Median TTR: 6.6 vs 10.3 mo ✔️ OS after recurrence worse with CROSS. ➡️ Relapse pattern impacts prognosis and follow-up strategy

Prospective study of stereotactic radiation for treatment of brain metastases (1-10) in SCLC (instead of whole brain radiation) Journal of Clinical Oncology. In 100 pts (median number of metastases was 2), only 22% of pts required salvage WBRT, mOS 10.2m. ascopubs.org/doi/10.1200/JC…

Most viewed this week from JAMA Oncology: Total neoadjuvant therapy (TNT) for stage II/III rectal cancer, despite variations in regimen choice, showed efficacy outcomes in routine clinical practice consistent with clinical trials. ja.ma/454REOi

Characterization of adenosquamous NSCLC and carcinosarcoma from The Shields Lab now JTO & JTO CRR. Actionable alterations (including METex14, EGFR, KRAS G12C, ALK, RET) seen in 37% of adenosquamous and in 17% of carcinosarcoma samples. jto.org/article/S1556-…

🚨 New opportunities in small-cell lung cancer. After decades of stagnation, advances in tumor heterogeneity, targetable surface proteins & biomarkers are reshaping SCLC treatment. A shift from modest gains to precision innovation. 📖 Nature Cancer 🔗 doi.org/10.1038/s43018…

🟠1L treatments of advanced pancreatic cancer ➡️mFOLFIRINOX or S-IROX vs Gem-nab-paclitaxel GENERATE, JCOG1611 Journal of Clinical Oncology ❌mFOLFIRINOX is not superior to Gem-nabPacli ❌No difference in OS, PFS and ORR 👉ascopubs.org/doi/pdf/10.120… ASCO OncoAlert #cancer #oncology #pancreatic

🫁 Evolving roles of MET as a therapeutic target in NSCLC and beyond. 🔹 MET alterations are reshaping the therapeutic landscape in NSCLC. 🔹 MET TKIs, antibodies, and ADCs (like telisotuzumab vedotin, FDA-approved May 2025) are expanding treatment options. 📖 NatureRevClinOncol

We do progress in small cell lung cancer, but still long way to go !

Defining high-risk pancreas #NETs🦓 496 resections 🇮🇹🇫🇷🇨🇦 Early recurrence 71% if venous thrombosis 41% if Ki 67>5% + tumor >3cm + ⬆️LN ⚠️Signs of biologically borderline-resectable NETs 🛑before resection ➡️ start with systemic💊 🔗journals.lww.com/annalsofsurger… Stefano Partelli

This is a great study, addressing something I have wanted to know for a long time. How good is the association between SSTR IHC and SSTR PET imaging? Can we rely on IHC instead of PET in resource restrained systems? What about tumor heterogeneity? mdpi.com/1422-0067/26/1…

New data from the randomized PEMBRO-RT study demonstrate when an ICI-mediated Abscopal effect is most likely to occur in patients with stage IV NSCLC. Ralph Weichselbaum Sean Pitroda, M.D. Amy L. Cummings, MD PhD doi.org/10.1038/s43018…

T-DXd Retreatment After ILD (Pooled analysis – 9 trials, 2145 pts) 🔹️23% of pts with G1 ILD were retreated 🔹️ILD recurrence in 33% (all G1–2, no G5) 🔹️20% discontinued due to ILD2 🔹️75% of steroid-treated pts recovered 💥 Retreatment appears feasible with proper

Claudin 18.2 in advanced gastric/GEJ adenocarcinoma – systematic review & meta-analysis 🔗 sciencedirect.com/science/articl… 📊 11 studies · 2,326 pts 🧬 Prognostic value inconsistent ⚠️ Heterogeneity in assays/cut‑offs 📏 Standardization essential